Tags

Type your tag names separated by a space and hit enter

Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha.
J Investig Med. 1999 May; 47(5):204-11.JI

Abstract

BACKGROUND

There is evidence for the role of inflammatory cytokines in the inhibition of erythropoiesis in the anemia of chronic disease, but the extent to which they contribute to resistance to erythropoietin (EPO) in patients with chronic renal failure is not clear. The purpose of the present study was to assess the effect of sera from patients with end-stage renal failure with and without infection or inflammatory disease on CFU-E colony formation in vitro.

METHODS

Bone marrow was obtained from uremic patients with inflammatory disease and from healthy controls. Standard colony assays were used to assess erythroid colony formation (CFU-E) in response to EPO in the presence or absence of 5% autologous serum. Normal bone marrow mononuclear cells were cultured with 5% v/v sera from three groups of patients: healthy volunteers, uremic controls, and uremic patients with inflammatory disease.

RESULTS

There was no difference between normal and uremic bone marrow response to EPO. However, when uremic/inflammatory bone marrow was cultured with autologous serum the optimal response to EPO was significantly inhibited. Optimal CFU-E colony formation was suppressed significantly by sera from either uremic group when compared with cultures containing sera from controls. Treatment of parallel cultures with a combination of antibodies to interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) almost completely restored the response to EPO. Additionally, bone marrow from healthy controls incubated with uremic sera showed an increased production of interleukin-1 alpha (IL-1 alpha) and IFN-gamma, and TNF-alpha was present in uremic sera.

CONCLUSIONS

CFU-E colony formation is inhibited by soluble factors present in the sera of uremic patients with or without inflammatory disease. These soluble factors stimulate the production of IFN-gamma and TNF-alpha, which directly inhibit erythropoiesis at a local level in the bone marrow.

Authors+Show Affiliations

Anthony Raine Research Laboratories, St. Bartholomew's, West Smithfield, London.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10361379

Citation

Allen, D A., et al. "Inhibition of CFU-E Colony Formation in Uremic Patients With Inflammatory Disease: Role of IFN-gamma and TNF-alpha." Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research, vol. 47, no. 5, 1999, pp. 204-11.
Allen DA, Breen C, Yaqoob MM, et al. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med. 1999;47(5):204-11.
Allen, D. A., Breen, C., Yaqoob, M. M., & Macdougall, I. C. (1999). Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research, 47(5), 204-11.
Allen DA, et al. Inhibition of CFU-E Colony Formation in Uremic Patients With Inflammatory Disease: Role of IFN-gamma and TNF-alpha. J Investig Med. 1999;47(5):204-11. PubMed PMID: 10361379.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. AU - Allen,D A, AU - Breen,C, AU - Yaqoob,M M, AU - Macdougall,I C, PY - 1999/6/11/pubmed PY - 1999/6/11/medline PY - 1999/6/11/entrez SP - 204 EP - 11 JF - Journal of investigative medicine : the official publication of the American Federation for Clinical Research JO - J Investig Med VL - 47 IS - 5 N2 - BACKGROUND: There is evidence for the role of inflammatory cytokines in the inhibition of erythropoiesis in the anemia of chronic disease, but the extent to which they contribute to resistance to erythropoietin (EPO) in patients with chronic renal failure is not clear. The purpose of the present study was to assess the effect of sera from patients with end-stage renal failure with and without infection or inflammatory disease on CFU-E colony formation in vitro. METHODS: Bone marrow was obtained from uremic patients with inflammatory disease and from healthy controls. Standard colony assays were used to assess erythroid colony formation (CFU-E) in response to EPO in the presence or absence of 5% autologous serum. Normal bone marrow mononuclear cells were cultured with 5% v/v sera from three groups of patients: healthy volunteers, uremic controls, and uremic patients with inflammatory disease. RESULTS: There was no difference between normal and uremic bone marrow response to EPO. However, when uremic/inflammatory bone marrow was cultured with autologous serum the optimal response to EPO was significantly inhibited. Optimal CFU-E colony formation was suppressed significantly by sera from either uremic group when compared with cultures containing sera from controls. Treatment of parallel cultures with a combination of antibodies to interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) almost completely restored the response to EPO. Additionally, bone marrow from healthy controls incubated with uremic sera showed an increased production of interleukin-1 alpha (IL-1 alpha) and IFN-gamma, and TNF-alpha was present in uremic sera. CONCLUSIONS: CFU-E colony formation is inhibited by soluble factors present in the sera of uremic patients with or without inflammatory disease. These soluble factors stimulate the production of IFN-gamma and TNF-alpha, which directly inhibit erythropoiesis at a local level in the bone marrow. SN - 1081-5589 UR - https://www.unboundmedicine.com/medline/citation/10361379/Inhibition_of_CFU_E_colony_formation_in_uremic_patients_with_inflammatory_disease:_role_of_IFN_gamma_and_TNF_alpha_ L2 - https://jim.bmj.com/lookup/pmidlookup?view=long&pmid=10361379 DB - PRIME DP - Unbound Medicine ER -